• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Streamex Corp. filed SEC Form 8-K: Financial Statements and Exhibits

    5/4/26 5:00:33 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STEX alert in real time by email
    false 0001530766 0001530766 2026-04-28 2026-04-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): April 28, 2026

     

    STREAMEX CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38659   26-4333375
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    2431 Aloma Avenue, Suite 243

    Winter Park, Florida

      32792
    (Address of principal executive offices)   (Zip Code)

     

    (203) 409-5444

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of exchange on which registered
    Common Stock, par value $0.001 per share   STEX   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Appointment of Director

     

    On April 28, 2026, the board of directors (the “Board”) of Streamex Corp. (the “Company”) appointed Mr. Mitchell Young Williams, the Company’s Chief Investment Officer, to serve as a non-independent director of the Board for a term expiring at the Company’s 2026 annual meeting of stockholders or until his successor is duly elected and qualified, or until the earlier of his death, resignation or removal.

     

    There are no arrangements or understandings between Mr. Williams and any other persons pursuant to which he was elected as a director of the Company. There are no family relationships between Mr. Williams and any other director or executive officer of the Company. There are no transactions between Mr. Williams and the Company that would be required to be reported under Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended, except as described below and the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 31, 2026, the relevant portions of which are incorporated herein by reference.

     

    Williams Amended Employment Agreement

     

    On April 28, 2026, the Company entered into an amended employment agreement, by and between the Company and Mitchell Young Williams, the Company’s Chief Investment Officer (the “Williams Employment Agreement”), effective April 6, 2026 (the “Effective Date”), which amends and restates that certain Employment Agreement, dated as of May 30, 2025, by and between the Company and Mr. Williams. Under the Williams Employment Agreement, Mr. Williams is entitled to receive an annual base salary of $350,000 starting the Effective Date. The Company shall review the annual salary annually and shall make any adjustments it determines are reasonable and as approved by the Board. Mr. Williams shall also be entitled to an annual bonus each year during his employment. For the 2026 fiscal year, Mr. Williams shall be entitled to a minimum annual bonus of no less than $100,000. In the event of a change in control the annual bonus for the fiscal year in which such change in control occurs will be at least 100% of the annual salary for that fiscal year. In addition, the Board granted Mr. Williams 1,250,000 restricted stock units for 2026 and a special incentive award for 1,000,000 restricted stock units, with both awards vesting in sixteen equal quarterly installments with the first vesting on July 1, 2026 and fifteen quarterly installments thereafter, in each case subject to continued service, and shall become fully vested upon a protected termination, a change in control, or the termination for any reason (including resignation) or demotion of the Company’s current Chief Executive Officer.

     

    The Williams Employment Agreement also includes customary confidentiality covenants, indemnification protections, directors’ and officers’ liability insurance coverage.

     

    If the Company terminates Mr. Williams without cause or if he resigns for good reason, in addition to accrued obligations, he shall also receive: an amount equal to twelve months of then in-effect annual salary payable in a single lump sum payment within thirty days following the date of termination; continued health, dental, and vision coverage (or reimbursement for the cost thereof) for a period of twelve months following the date of termination; a prorated annual bonus for the year of termination, and full accelerated vesting of any unvested RSUs or other equity granted by the Company. In the event of termination due to Mr. Williams’ death or disability, in addition to accrued obligations, Mr. Williams (or his estate) shall also receive a prorated annual bonus for the year of termination.

     

     

     

     

    The foregoing summary is qualified in its entirety by reference to the Williams Employment Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and which is incorporated herein by reference.

     

    McPhie Amended Employment Agreement

     

    On May 1, 2026, the Company entered into an amended employment agreement with Karl Henry McPhie, the Company’s Chief Executive Officer (the “McPhie Employment Agreement”), effective May 1, 2026 (the “Effective Date”), which amends and restates that certain Employment Agreement, dated as of November 18, 2025, by and between the Company and Mr. McPhie. Under the McPhie Employment Agreement, Mr. McPhie will receive an annual base salary of $350,000 USD, effective April 1, 2026 (that may be paid in equivalent Canadian dollars) and a one-time salary adjustment bonus of $31,250 USD which equals the prorated difference between such salaries for the period from January 1, 2026 through April 1, 2026. Mr. McPhie will be allowed to receive up to 50% of the annual salary paid in GLDY. The Company shall review the annual salary annually and shall make any adjustments it determines are reasonable and as approved by the Board.

     

    In addition, the Board granted Mr. McPhie 1,500,000 Performance Stock Units for shares of the Company’s common stock (the “2026 PSU Award”), divided into five (5) equal tranches of three hundred thousand (300,000) shares each. Each tranche will vest upon the Company’s cumulative sales of GLDY reaching the corresponding milestone, as follows: Tranche 1 vests upon cumulative GLDY sales reaching US$250,000,000; Tranche 2 vests upon cumulative GLDY sales reaching US$500,000,000; Tranche 3 vests upon cumulative GLDY sales reaching US$1,000,000,000; Tranche 4 vests upon cumulative GLDY sales reaching US$2,000,000,000; and Tranche 5 vests upon cumulative GLDY sales reaching US$3,000,000,000. Cumulative GLDY sales shall be measured by the Company in good faith and certified by the Committee. Vesting of any tranche is subject to Mr. McPhie’s continuous employment through the date the applicable milestone is achieved, except that the 2026 PSU Award will become fully vested upon (i) a Protected Termination, or (ii) a Change in Control. Any tranche of the 2026 PSU Award that has not vested on or before the tenth (10th) anniversary of the Effective Date shall be forfeited.

     

    Subject to the approval of the Board, Mr. McPhie shall be entitled to an annual bonus each year during his employment. For the 2026 fiscal year, Mr. McPhie shall be entitled to a minimum annual bonus of no less than $100,000. In the event of a change in control, the annual bonus for the fiscal year in which such change in control occurs shall be at least 100% of the annual salary for that fiscal year. Any annual bonus shall be subject to any clawback or recoupment policy adopted by the Company, including any policy adopted to comply with applicable law or stock exchange listing requirements.

     

    The McPhie Employment Agreement also provides for market capitalization milestone bonuses. Mr. McPhie shall be eligible for one-time awards under the Company’s equity plan upon the Company achieving and maintaining certain fully diluted market capitalization levels based on a volume-weighted average price over a trailing, consecutive thirty trading day period, as follows: (i) upon achieving a $50 billion market capitalization, a one-time bonus equivalent to $100,000,000 payable in cash or shares at the Board’s election, plus 5,000,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”); (ii) upon achieving a $100 billion market capitalization, a one-time bonus equivalent to $250,000,000 payable in cash or shares at the Board’s election, a one-time cash bonus of $50,000,000 payable in cash or shares at the employee’s election, plus 10,000,000 shares of Common Stock; and (iii) upon achieving a $500 billion market capitalization, a one-time bonus equivalent to $500,000,000 payable in cash or shares at the Board’s election, a one-time cash bonus of $250,000,000 payable in cash or shares at the employee’s election, plus 20,000,000 shares of Common Stock. Any such awards are subject to equity plan limits and applicable law.

     

    The McPhie Employment Agreement includes customary confidentiality, indemnification, and director and officer insurance protections and provides that, if the Company terminates Mr. McPhie without cause, if he resigns for good reason, in addition to accrued obligations, he will be entitled to severance benefits consisting of an amount equal to twelve months of then in-effect annual salary, continued health, dental, and vision coverage (or reimbursement for the cost thereof) for a period of twelve months, a prorated annual bonus for the year of termination, and full accelerated vesting of any unvested RSUs or other equity granted by the Company.

     

    The foregoing summary is qualified in its entirety by reference to the McPhie Employment Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.2 and which is incorporated herein by reference.

     

     

     

     

    Lekstrom Amended Employment Agreement

     

    On May 1, 2026, the Company entered into an amended employment agreement with Morgan Lekstrom, the Company’s Interim Executive Chairman (the “Lekstrom Employment Agreement”), effective May 1, 2026, which amends and restates that certain Employment Agreement, dated as of November 18, 2025, by and between the Company and Mr. Lekstrom. Under the Lekstrom Employment Agreement, Mr. Lekstrom shall receive an annual base salary of $350,000 USD, effective February 9, 2026 (that may be paid in equivalent Canadian dollars). Mr. Lekstrom will be allowed to receive up to 50% of the annual salary paid in GLDY. The Company shall review the annual salary annually and shall make any adjustments it determines are reasonable and as approved by the Board.

     

    In addition, the Board granted Mr. Lekstrom 1,500,000 Performance Stock Units for shares of the Company’s common stock (the “2026 PSU Award”), divided into five (5) equal tranches of three hundred thousand (300,000) shares each. Each tranche will vest upon the Company’s cumulative sales of GLDY reaching the corresponding milestone, as follows: Tranche 1 vests upon cumulative GLDY sales reaching US$250,000,000; Tranche 2 vests upon cumulative GLDY sales reaching US$500,000,000; Tranche 3 vests upon cumulative GLDY sales reaching US$1,000,000,000; Tranche 4 vests upon cumulative GLDY sales reaching US$2,000,000,000; and Tranche 5 vests upon cumulative GLDY sales reaching US$3,000,000,000. Cumulative GLDY sales shall be measured by the Company in good faith and certified by the Committee. Vesting of any tranche is subject to Mr. Lekstrom’s continuous employment through the date the applicable milestone is achieved, except that the 2026 PSU Award will become fully vested upon (i) a Protected Termination, or (ii) a Change in Control. Any tranche of the 2026 PSU Award that has not vested on or before the tenth (10th) anniversary of the Effective Date shall be forfeited.

     

    The Lekstrom Employment Agreement also provides for market capitalization milestone bonuses. Mr. Lekstrom shall be eligible for one-time awards under the Company’s equity plan upon the Company achieving and maintaining certain fully diluted market capitalization levels based on a volume-weighted average price over a trailing, consecutive thirty trading day period, as follows: (i) upon achieving a $50 billion market capitalization, a one-time bonus equivalent to $100,000,000 payable in cash or shares at the Board’s election, plus 5,000,000 shares of Common Stock; (ii) upon achieving a $100 billion market capitalization, a one-time bonus equivalent to $250,000,000 payable in cash or shares at the Board’s election, a one-time cash bonus of $50,000,000 payable in cash or shares of Common Stock at the employee’s election, plus 10,000,000 shares of Common Stock; and (iii) upon achieving a $500 billion market capitalization, a one-time bonus equivalent to $500,000,000 payable in cash or shares at the Board’s election, a one-time cash bonus of $250,000,000 payable in cash or shares at the employee’s election, plus 20,000,000 shares of Common Stock.

     

    The Lekstrom Employment Agreement includes customary confidentiality, indemnification, and director and officer insurance protections and provides that, if the Company terminates Mr. Lekstrom without cause, if he resigns for good reason, in addition to accrued obligations, he will be entitled to severance benefits consisting of an amount equal to twelve months of then in-effect annual salary, continued health, dental, and vision coverage (or reimbursement for the cost thereof) for a period of twelve months, a prorated annual bonus for the year of termination, and full accelerated vesting of any unvested RSUs or other equity granted by the Company.

     

    The foregoing summary is qualified in its entirety by reference to the Lekstrom Employment Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.3 and which is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    10.1   Amended Employment Agreement between Streamex Corp. and Mitchell Williams, dated April 28, 2026
    10.2   Amended Employment Agreement between Streamex Corp. and Karl Henry McPhie, dated May 1, 2026
    10.3   Amended Employment Agreement between Streamex Corp. and Morgan Lekstrom, dated May 1, 2026
    104   Cover Page Interactive Data File (formatted as Inline XBRL)

      

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      STREAMEX CORP.
         
    Date: May 4, 2026 By: /s/ Karl Henry McPhie
      Name: Karl Henry McPhie
      Title: Chief Executive Officer

     

     

     

    Get the next $STEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STEX

    DatePrice TargetRatingAnalyst
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Williams Mitchell Young sold $24,915 worth of shares (23,810 units at $1.05), decreasing direct ownership by 0.78% to 3,013,838 units (SEC Form 4) to satisfy withholding obligation

    4 - Streamex Corp. (0001530766) (Issuer)

    6/2/26 9:54:16 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 4 filed by Interim Executive Chairman Lekstrom Morgan Lee

    4/A - Streamex Corp. (0001530766) (Issuer)

    5/28/26 9:44:06 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: Interim Executive Chairman Lekstrom Morgan Lee bought $147,289 worth of shares (47,000 units at $3.13) (SEC Form 4)

    4/A - Streamex Corp. (0001530766) (Issuer)

    5/28/26 9:43:32 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. and Orca Announce Launch of 24/7 Decentralized Secondary Liquidity Infrastructure for Tokenized Securities; GLDY the Inaugural Asset

    WINTER PARK, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the launch of 24/7 secondary liquidity infrastructure for holders to trade tokenized securities, developed in partnership with Orca, a leading automated market maker (AMM) infrastructure provider on the Solana blockchain. Streamex's GLDY, a gold-backed, yield-bearing tokenized security, is the inaugural asset to trade on this infrastructure, in the "GLDY Pool on Orca." This marks a significant milestone for the broader tokenized real-world asset market as a vital piece of

    5/27/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

    WINTER PARK, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the appointment of Kori Handy as Vice President of Product and Design. Kori brings 18 years of experience scaling fintech and SaaS platforms from zero to $2B+ in assets under management and more than 200 million users, and joins Streamex at a pivotal moment in the Company's growth trajectory. Highlights Kori brings nearly two decades of product, design, and startup leadership experience building fintech and SaaS platforms used by more than 200 million p

    5/26/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Provides Q1 2026 Earnings and Corporate Update Presentation Recap; Highlights New Partnerships & Key Updates

    WINTER PARK, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, yesterday hosted its Q1 2026 Earnings and Corporate Update Presentation, featuring remarks from Executive Chairman Morgan Lekstrom, Chief Executive Officer Henry McPhie, Chief Financial Officer Christine Plummer, and Chief Investment Officer Mitch Williams. The following is a summary of the key topics covered. Highlights Equity Trust - access to $72B+ and 359,000 U.S. tax-advantaged retirement accounts. An upcoming integration with Equity Trust Company opens GLDY to a distribution channel that prev

    5/21/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Interim Executive Chairman Lekstrom Morgan Lee bought $147,289 worth of shares (47,000 units at $3.13) (SEC Form 4)

    4/A - Streamex Corp. (0001530766) (Issuer)

    5/28/26 9:43:32 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Interim Executive Chairman Lekstrom Morgan Lee bought $49,980 worth of shares (34,000 units at $1.47) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    5/28/26 2:33:28 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Marciano Anthony Mark bought $20,052 worth of shares (17,745 units at $1.13), increasing direct ownership by 18% to 117,745 units (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    5/22/26 4:05:25 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    5/28/26 4:05:31 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    5/27/26 6:05:10 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Streamex Corp.

    10-Q - Streamex Corp. (0001530766) (Filer)

    5/14/26 5:24:55 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. Appoints Former Microsoft and PayPal Lead Product Designer Kori Handy as Vice President of Product and Design

    WINTER PARK, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the appointment of Kori Handy as Vice President of Product and Design. Kori brings 18 years of experience scaling fintech and SaaS platforms from zero to $2B+ in assets under management and more than 200 million users, and joins Streamex at a pivotal moment in the Company's growth trajectory. Highlights Kori brings nearly two decades of product, design, and startup leadership experience building fintech and SaaS platforms used by more than 200 million p

    5/26/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

    WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company's global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Str

    3/16/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

    WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment of Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. and Founder and Chief Investment Officer of Hondius Capital Management, to its Board of Directors. In this role, Mr. Matthews will bring decades of global investment, trading, and executive leadership experience to support Streamex's strategic growth, capital markets initiatives, and governance. He is joining as an independent director. Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex sa

    3/3/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. Provides Q1 2026 Earnings and Corporate Update Presentation Recap; Highlights New Partnerships & Key Updates

    WINTER PARK, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, yesterday hosted its Q1 2026 Earnings and Corporate Update Presentation, featuring remarks from Executive Chairman Morgan Lekstrom, Chief Executive Officer Henry McPhie, Chief Financial Officer Christine Plummer, and Chief Investment Officer Mitch Williams. The following is a summary of the key topics covered. Highlights Equity Trust - access to $72B+ and 359,000 U.S. tax-advantaged retirement accounts. An upcoming integration with Equity Trust Company opens GLDY to a distribution channel that prev

    5/21/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Announces April 2026 Yield Dividend Distribution for GLDY

    WINTER PARK, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, today announced the distribution of the second yield payment for GLDY, its gold-backed, yield-bearing tokenized security. The distribution covers the period from April 1st through April 30th, 2026. Yield Distribution Details GLDY's real-world yield is generated through Streamex's institutional gold leasing program, with proceeds from the program distributed to GLDY holders in the form of additional GLDY tokens monthly. Gold on lease is currently earning an annualized lease yield of 3.5%. For the mo

    5/18/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Reports Q1 2026 Financial Results and Announces Business & Quarterly Update Call

    WINTER PARK, Fla., May 14, 2026 (GLOBE NEWSWIRE) --  Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology company focused on the tokenization of commodity real-world assets, today announced that it has filed its Q1 2026 financial results and will host an earnings and corporate update presentation on Wednesday, May 20, 2026, at 4:30 p.m. ET. Henry McPhie, Co-Founder & Chief Executive Officer of Streamex, said: "Q1 2026 was a transformative quarter for Streamex. We raised over $40 million in equity capital, fully deleveraged our balance sheet, and launched GLDY. We made our first yield distribution to GLDY holders, paying investors in gold to hold gold for the first tim

    5/14/26 6:01:22 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care